Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists

doi:10.5500/wjt.120572

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article (XML)

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Transplant. Sep 18, 2026; 16(3): 120572
Published online Sep 18, 2026. doi: 10.5500/wjt.120572

Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists

Soha Elatrebi, Rowan Abuyadek, Sohaila Mohamed Mohamed Abdelbar, Muhammad S Ahmad, Mohamed Ayyad, Muhammad AbdelAziz Quoritem, Rodaina Osama Abdel Majid, Manar Arafat, Ahmed Amgad, Amr Alnagar

Soha Elatrebi, Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria 21526, Al Iskandarīyah, Egypt

Soha Elatrebi, Department of Clinical Pharmacology, College of Medicine, Arab Academy for Science, Technology and Maritime Transport, Alamain 44791, Egypt

Rowan Abuyadek, Department of Health Administration and Behavioral Sciences (Hospital Administration Specialty), High Institute of Public Health, Alexandria University, Alexandria 21561, Egypt

Sohaila Mohamed Mohamed Abdelbar, Medical Intern, Kasralainy Medical Hospitals, Cairo University, Cairo 12613, Al Qāhirah, Egypt

Muhammad S Ahmad, Department of General Surgery, The Dudley Group NHS Foundation Trust, Dudley DY1 2HQ, United Kingdom

Mohamed Ayyad, Department of Upper GIT Surgery, University Hospitals of Birmingham, Birmingham B9 5SS, United Kingdom

Muhammad AbdelAziz Quoritem, Department of Nephrology, Alsabah Hospital, Farwaneya 00965, Kuwait

Rodaina Osama Abdel Majid, Department of Public Health, High Institute of Public Health Alexandria, Alexandria University, Alexandria 21531, Al Iskandarīyah, Egypt

Manar Arafat, Department of General Surgery, Royal Glamorgan Hospital, Cwm Taf Morgannwg University Health Board, Rhondda CF72 8XR, Rhondda Cynon Taff, United Kingdom

Ahmed Amgad, Faculty of Medicine, Helwan University, Cairo 4034572, Al Qāhirah, Egypt

Amr Alnagar, Department of General Surgery, University Hospitals of Birmingham, Birmingham B9 5SS, United Kingdom

Author contributions: Elatrebi S, Abuyadek R, Abdelbar SMM, Ahmad MS, Ayyad M, Quoritem MA, Abdel Majid RO, and Arafat M conducted the literature review and wrote the manuscript draft; Elatrebi S and Alnagar A performed the critical revision and final drafting of the manuscript; Amgad A and Alnagar A designed the study; all of the authors read and approved the final version of the manuscript to be published.

AI contribution statement: Non-subscription ChatGPT was used only for language editing and polishing. It was not involved in idea creation, literature review or final drafting.

Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.

Corresponding author: Amr Alnagar, PhD, Department of General Surgery, University Hospitals of Birmingham, 6 Chamberlain Road, Birmingham B9 5SS, United Kingdom. amr.alnagar@nhs.net

Received: March 2, 2026
Revised: March 18, 2026
Accepted: May 19, 2026
Published online: September 18, 2026
Processing time: 182 Days and 13.3 Hours

Core Tip

Core Tip: While liver transplantation can be life-saving for end-stage liver diseases, it can exacerbate metabolic issues due to underlying pathology and immunosuppressive regimens. A thorough management plan is essential to prevent complications like metabolic dysfunction-associated steatotic liver disease, chronic renal dysfunction, and diabetes, ultimately improving prognosis and quality of life. glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists have gained United States Food and Drug Administration approval for long-term weight management, but their long-term safety, optimal dosing, and effectiveness in transplant recipients remain underexplored. This review addresses the pathophysiology, risk factors, and burden of metabolic complications in liver transplant recipients while evaluating the potential role of GLP-1 and GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists for managing these issues.